Rachel Kaczynski, DO
Surgical Oncology · San Antonio, TXNPI 1487942736
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), food and beverage and entertainment — rather than concentrated in one kind of arrangement. KUB Technologies Inc. accounts for 61.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $1,863 and has fallen 95.3% since, to $88 in 2025.
Across 16 payments — averaging $181.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KUB Technologies Inc.$2K
- Myriad Genetic Laboratories, Inc.$415
- Endomagnetics Ltd$207
- AstraZeneca$125
- Genmab U.S., Inc.$125
- Immunogen, Inc.$125
- plus $129 from 6 others
What the payments were for
- Speaking & faculty fees$1,50052%
- Food & beverage$1,15740%
- Entertainment$2458%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KUB Technologies Inc. | 3 | $1,776 |
| Myriad Genetic Laboratories, Inc. | 2 | $415 |
| Endomagnetics Ltd | 2 | $207 |
| AstraZeneca | 1 | $125 |
| Genmab U.S., Inc. | 1 | $125 |
| Immunogen, Inc. | 1 | $125 |
| Acell, Inc. | 1 | $34 |
| Pharmacosmos Therapeutics Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $18 |
| Kerecis Limited | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,902 in reported general payments places this provider in the 60th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine-PrilocaineLidocaine/Prilocaine | 37 | $506 |
| Celecoxib | 19 | $258 |
| Tramadol Hcl | 66 | $110 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in San Antonio
- Alfredo Santillan GomezSan Antonio$125K
- Mio KitanoSan Antonio$32K
- Farbod MalekSan Antonio$16K
- Maryam ElmiSan Antonio$12K
- Allan WhiteSan Antonio$5K
- Alexander ParikhSan Antonio$5K
- Federico TozziSan Antonio$4K
- Allison DipasqualeDallas$272K
- Merrick RossHouston$216K
- John HardawayShenandoah$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.